Topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor expected by the end of the third quarter of 2022
On track to initiate a proof-of-concept clinical trial with ELX-02 in up to eight Alport syndrome patients with nonsense mutations in the second half of 2022
On track to submit an Investigational New Drug (IND) application for the inhaled delivery of ELX-02 in the fourth quarter of 2022
On track to submit IND application for ZKN-013 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) patients with nonsense mutations cells in the fourth quarter of 2022
Announces results of ZKN-013 Dose Response Study in APCMin Model that confirmed the results from prior study which concluded in
Cash and equivalents expected to be sufficient to fund operations into the fourth quarter of 2023
“We continue to make significant progress advancing our pipeline of novel products for patients with substantial unmet medical needs. With multiple potential value-creating events expected over the next twelve months, including topline data readouts for ELX-02 in both CF and Alport syndrome, we are approaching an exciting and eventful period for the company,” said
Second Quarter 2022 and Subsequent Highlights
Class 1 Cystic Fibrosis
- Phase 2 clinical trials in CF patients, with expansion arms designed to evaluate the safety of ELX-02 and assess short-term biological activity in patients, remains ongoing. Topline results are expected before the end of the third quarter of 2022 once complete patient data sets are received.
- A head-to-head preclinical study of inhaled (nebulizer-based) delivery of the current subcutaneous formulation of ELX-02 compared to subcutaneous dosing in a CF rodent model has been completed with data analysis ongoing. Human exposure, modeled based on previous animal pharmacokinetic studies, suggests that the lung drug exposure with inhaled delivery of ELX-02 is at least 50-fold greater than with subcutaneous delivery. Higher drug exposure, achievable with inhaled delivery, has been associated with 3 to 6 fold higher activity in CF models. We expect to report topline results before the end of the third quarter of 2022 and remain on track to submit an IND application in the fourth quarter of 2022.
- Eloxx previously announced it has expanded its clinical development pipeline to include the potential treatment with ELX-02 of a subset of Alport Syndrome patients with nonsense mutations in the Collagen Type 4 genes, (COL4A3, COL4A4, and COL4A5). Alport syndrome is a rare genetic disorder characterized by kidney disease with high levels of proteinuria, hearing loss and eye abnormalities.
- Eloxx remains on track to initiate a proof-of-concept clinical trial in up to eight Alport syndrome patients with nonsense mutations in the second half of 2022. Patients will be dosed for two months with a three month follow-up. Trial primary endpoints include safety while secondary endpoints are reduction in proteinuria and induction of COL4A5 protein expression in the kidney. Initial topline results are expected in the first half of 2023.
Recessive Dystrophic Epidermolysis Bullosa and Junctional Epidermolysis Bullosa (JEB)
- Eloxx continues to expect to file an IND application in the fourth quarter of 2022 and be ready to start a First in Human (FIH) Phase 1 study with ZKN-013 after recently completing 28-day non Good Laboratory Practice (GLP) animal studies.
Familial Adenomatous Polyposis
- Eloxx today announced positive results from a repeat study in the APCMin (multiple intestinal neoplasia) model evaluating the potential of ZKN-013 to treat FAP. These results provide further confirmation of ZKN-013’s potential to treat FAP, following the previously reported single-dose data in the APCMin model. The APCMin mouse is a translationally validated model for drug development for FAP, a rare inherited disease, with no approved drug therapies, characterized by proliferation of colon polyps. Eloxx is targeting a subset of patients that have nonsense mutations in the Adenomatous Polyposis Coli (APC) gene that is truncated in these patients.
- In the repeat study, APCMin mice received daily oral doses of ZKN-013 at 50, 25, 12.5 mg/kg body weight for 8 weeks.
- 100% survival was achieved at the lowest dose of ZKN-013 tested.
- ZKN-013 significantly lessened anemic conditions, generally considered to be the major cause of animal death associated with APCMin model.
- Eloxx intends to file an IND application to the
U.S. Food and Drug Administrationfor ZKN-013 for the treatment of FAP in the second half of 2023.
Second Quarter 2022 Financial Results
For the three months ended
Our R&D expenses were
Our general and administrative (G&A) expenses were
For more information, please visit www.eloxxpharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical facts contained in this press release, including without limitation, statements regarding our future financial results, our cash runway, the expected timing of trials and results from clinical studies of our product candidates and the potential of our product candidate to treat nonsense mutations are forward-looking statements. Forward-looking statements can be identified by the words “aim,” “may,” “will,” “would,” “should,” “expect,” “explore,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “seeks,” or “continue” or the negative of these terms similar expressions, although not all forward-looking statements contain these words.
Forward-looking statements are based on management's current plans, estimates, assumptions and projections based on information currently available to us. Forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and actual results or outcomes may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: our ability to progress any product candidates in preclinical or clinical trials; the uncertainty of clinical trial results and the fact that positive results from preclinical studies are not always indicative of positive clinical results; the scope, rate and progress of our preclinical studies and clinical trials and other research and development activities; the competition for patient enrollment from drug candidates in development; the impact of the global COVID-19 pandemic on our clinical trials, operations, vendors, suppliers, and employees; our ability to obtain the capital necessary to fund our operations; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain financial in the future through product licensing, public or private equity or debt financing or otherwise; general business conditions, regulatory environment, competition and market for our products; and business ability and judgment of personnel, and the availability of qualified personnel and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended
All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
|UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS|
|(Amounts in thousands, except share and per share data)|
|Cash and cash equivalents||$||30,048||$||42,268|
|Prepaid expenses and other current assets||1,281||913|
|Total current assets||31,592||43,480|
|Property and equipment, net||190||216|
|Operating lease right-of-use assets||1,159||1,443|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Current portion of long-term debt||1,125||-|
|Advances from collaboration partners||10,723||3,723|
|Current portion of operating lease liabilities||686||657|
|Total current liabilities||19,504||9,955|
|Long-term debt, net of current portion||11,129||11,996|
|Operating lease liabilities||496||804|
|Total stockholders’ equity||1,812||22,384|
|Total liabilities and stockholders' equity||$||32,941||$||45,139|
|UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS|
|(Amounts in thousands, except share and per share data)|
|Three Months Ended||Six Months Ended|
|June 30,||June 30,|
|Research and development||$||7,651||$||5,704||$||15,550||$||9,777|
|General and administrative||2,645||7,355||5,699||11,696|
|In process research and development||—||22,670||—||22,670|
|Total operating expenses||10,296||35,729||21,249||44,143|
|Loss from operations||(10,296||)||(35,729||)||(21,249||)||(44,143||)|
|Other expense, net||322||329||989||609|
|Net loss per share, basic and diluted||$||(0.12||)||$||(0.54||)||$||(0.26||)||$||(0.84||)|
|Weighted average number of shares of common stock used in computing net loss per share, basic and diluted||86,654,120||66,389,865||86,652,587||53,357,401|
Source: Eloxx Pharmaceuticals